How to Get Zetia in Hawaii: Prescription, Telehealth, and Pharmacy Guide

What Is Ezetimibe and Why Do Hawaii Patients Need It?

Ezetimibe blocks the Niemann-Pick C1-Like 1 (NPC1L1) cholesterol transporter in the small intestinal brush border, reducing LDL-C by 18 to 25% as monotherapy and by an additional 21 to 27% when added to a statin [1]. For Hawaii residents who cannot tolerate adequate statin doses, or whose LDL-C remains above the ACC/AHA goal despite maximum-tolerated statin therapy, ezetimibe is the first add-on the 2018 ACC/AHA Guideline on the Management of Blood Cholesterol recommends [2].

Hawaii has some of the highest rates of cardiovascular disease among Native Hawaiian and Pacific Islander populations. According to the CDC, heart disease is the leading cause of death in Hawaii, accounting for roughly 24% of all-cause mortality in the state [3]. Ezetimibe's evidence base is anchored in the IMPROVE-IT trial (N=18,144), which randomized post-ACS patients to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo. At 7 years, the combination arm reached a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the placebo arm, producing a 6.4% relative risk reduction in major adverse cardiovascular events (P<0.001) [4]. That absolute benefit translates to roughly 2 fewer MACE events per 100 high-risk patients treated over 7 years [4].

The FDA approved ezetimibe (NDA 021445) in October 2002 for primary hyperlipidemia and homozygous familial hypercholesterolemia, and the current prescribing information is available on the FDA's Drugs@FDA database [5]. Because it is a Schedule-exempt prescription drug with no federal controlled-substance classification, Hawaii providers face no DEA-registration barrier to prescribing it via telehealth.

How to Get a Zetia Prescription in Hawaii

The fastest path is a telehealth visit with a Hawaii-licensed provider, which can convert to an e-prescription sent to a local or mail-order pharmacy the same day. A fasting lipid panel and a brief medication history are all most providers need at the initial visit.

Hawaii follows the Federation of State Medical Boards' telehealth framework and the Hawaii Telehealth Act (HRS §453-1.3), which authorizes prescribing via synchronous audio-visual consultation without requiring a prior in-person examination [6]. This means a patient in Hilo, Kauai, or Molokai who cannot easily reach a cardiologist can complete a video visit from a smartphone and receive an e-prescription within minutes of the appointment ending.

The standard clinical pathway runs as follows. First, schedule a telehealth or in-person appointment and disclose your current medications, any prior statin intolerance, and any allergy history. Second, have a fasting lipid panel drawn within the previous 12 months (most telehealth platforms can order labs at Quest Diagnostics or LabCorp locations across Oahu, Maui, and the Big Island before the visit). Third, the provider reviews your LDL-C goal based on ASCVD risk category per the 2018 ACC/AHA guidelines [2], determines that ezetimibe is appropriate, and transmits the prescription electronically. Fourth, pick up at a retail pharmacy or elect 90-day mail-order supply.

HealthRX providers operate under Hawaii medical licenses and can prescribe ezetimibe to patients in all Hawaii counties. Visits typically run 15 to 20 minutes. Documentation submitted to the patient's chart includes the indication, goal LDL-C, and any statin history, all of which supports any subsequent prior-authorization filing.

Lab Requirements Before Ezetimibe in Hawaii

A fasting lipid panel is the only mandatory lab; liver function tests are recommended at baseline but not strictly required by FDA labeling for ezetimibe alone.

The ACC/AHA 2018 guideline recommends obtaining a fasting lipid panel to confirm the LDL-C level before initiating any non-statin lipid-lowering therapy [2]. For Hawaii patients, Quest Diagnostics operates patient service centers in Honolulu, Aiea, Kailua-Kona, and Kahului, and LabCorp has draw sites on Oahu and Maui. Results are typically available within 24 hours. If you already have a lipid panel drawn within the past 12 months with documented LDL-C above your risk-stratified goal, most Hawaii telehealth providers will accept that result and proceed without ordering a repeat draw.

Ezetimibe does not require CK monitoring, thyroid function tests, or HbA1c before initiation. If you are combining ezetimibe with a statin, the ACC/AHA advises checking ALT and AST at baseline because statin-related hepatotoxicity, though rare (incidence roughly 1 in 100,000 patient-years per the FDA statin label class review [7]), is a clinically relevant safety signal.

Patients with suspected sitosterolemia (plant sterol accumulation disorder) should have plant sterol levels checked before starting ezetimibe, since the drug can paradoxically raise plant sterol absorption in that condition. This is a rare scenario but relevant in Hawaii's genetically diverse population.

Who Can Prescribe Zetia in Hawaii?

Any Hawaii-licensed MD, DO, nurse practitioner (NP), or physician assistant (PA) can prescribe ezetimibe. Pharmacists with prescribing authority under a collaborative practice agreement can also issue it in some clinical settings.

Hawaii's Nurse Licensure Compact membership and its Advanced Practice Registered Nurse statute (HRS §457-8.6) give NPs full prescriptive authority for non-controlled drugs without physician supervision [8]. PAs in Hawaii hold prescriptive authority under HRS §453-5.3 and can prescribe ezetimibe independently within their scope of practice documentation. This breadth of prescriber eligibility is relevant for telehealth platforms, where NPs and PAs often staff a large share of the clinician roster.

Cardiologists, endocrinologists, and lipid specialists at Queen's Medical Center, Straub Medical Center, and Hawaii Pacific Health system facilities frequently manage ezetimibe as part of a combined lipid-lowering regimen. For patients who prefer an in-person specialist consultation, a referral from a primary-care provider is typically required by most Hawaii commercial insurers before seeing a lipid specialist.

Telehealth Providers in Hawaii Prescribing Zetia

Synchronous telehealth is the dominant pathway for ezetimibe access in Hawaii's neighbor-island communities, where specialist density is low.

Hawaii's neighbor islands, particularly Molokai, Lanai, and rural areas of the Big Island, have historically faced physician shortages. According to the Hawaii State Center for Nursing, physician-to-patient ratios on some neighbor islands are below half the national average [9]. Telehealth closes this gap for non-urgent lipid management. Platforms that hold an active Hawaii medical license can prescribe ezetimibe to patients anywhere in the state after a synchronous video visit.

HealthRX conducts visits via HIPAA-compliant video, collects a structured cardiac risk history, reviews your most recent lipid panel, and transmits an e-prescription to the Hawaii pharmacy of your choice or to a mail-order fulfillment center that delivers to all zip codes in the state including 96700 to 96898. After the initial visit, follow-up can be asynchronous (secure message) or via a 10-minute check-in visit at the 6-week mark to confirm LDL-C response.

The Hawaii Medical Board requires telehealth providers to meet the same standard of care as in-person providers [6]. This includes documenting the clinical rationale for prescribing, the patient's allergy list, relevant comorbidities, and the LDL-C target being pursued.

Zetia Pharmacy Options in Hawaii

Retail chains, independent pharmacies, and mail-order services all dispense ezetimibe in Hawaii, and 503A compounding pharmacies can prepare patient-specific formulations when standard tablets are not appropriate.

Retail pharmacies. CVS, Longs Drugs (CVS Health's Hawaii brand), Walgreens, and Costco Pharmacy locations on Oahu, Maui, and the Big Island stock generic ezetimibe 10 mg. GoodRx pricing as of mid-2025 places a 30-day supply of generic ezetimibe at $12 to $28 at these chains. Brand-name Zetia costs $300 to $400 per month without insurance, which makes generic substitution the standard default in Hawaii [10].

Mail-order pharmacies. Express Scripts, CVS Caremark, and OptumRx all deliver to Hawaii residential addresses. Mail-order 90-day supplies often reduce out-of-pocket cost by 20 to 30% compared to 30-day retail fills under commercial insurance formularies [11]. Delivery to most Hawaii zip codes takes 3 to 5 business days via USPS Priority or FedEx, though outer-island delivery to Molokai or Lanai may take 5 to 7 days.

503A compounding pharmacies. Licensed 503A pharmacies in Hawaii can prepare patient-specific ezetimibe formulations (for example, a liquid suspension for patients with swallowing difficulties) under a valid prescription. Hawaii's Board of Pharmacy licenses compounding pharmacies under HRS §461-11.5, and facilities must comply with USP Chapter 795 standards [12]. Note that compounded ezetimibe is not AB-rated equivalent to branded Zetia and does not carry FDA bioequivalence approval; clinical use is reserved for documented need such as tablet dysphagia or a verified allergy to the commercial formulation's inactive ingredients.

Specialty pharmacies. For patients with familial hypercholesterolemia who are combining ezetimibe with a PCSK9 inhibitor such as evolocumab or alirocumab, specialty pharmacy coordination through Accredo or BioPlus may be needed for the PCSK9 component. Ezetimibe itself does not require a specialty pharmacy.

Prior Authorization for Zetia in Hawaii

Most Hawaii commercial insurers place ezetimibe on Tier 2 or Tier 3 with a prior-authorization requirement, and Hawaii Med-QUEST (Medicaid) does not routinely cover it.

Prior authorization (PA) for ezetimibe in Hawaii typically requires the prescriber to document two things: first, that the patient has been on a maximally tolerated statin for at least 90 days; and second, that LDL-C remains above the goal for the patient's ASCVD risk category as defined by the 2018 ACC/AHA Cholesterol Guideline [2]. For very high-risk patients (prior ACS, established ASCVD), the goal is LDL-C <70 mg/dL; for high-risk patients without prior events, the goal is LDL-C <100 mg/dL [2].

HMSA (Hawaii Medical Service Association), the state's largest commercial insurer, lists ezetimibe on its formulary with PA for members who have not tried a statin or who have not documented statin intolerance. UnitedHealthcare and Kaiser Permanente Hawaii have similar step-therapy requirements. Documentation that satisfies PA nearly always includes a recent lipid panel result, a prescription or dispensing record showing statin use, and a provider attestation of intolerance if applicable.

Hawaii Med-QUEST managed care plans (AlohaCare, HMSA's Quest, Kaiser Quest, and United Healthcare Community Plan) do not include ezetimibe on the preferred drug list as of 2025. Patients enrolled in Med-QUEST who need ezetimibe require a non-formulary exception, which the prescriber files by submitting documentation of medical necessity. Approval rates for non-formulary exceptions when clinical criteria are met are not publicly reported, but the process typically adds 5 to 10 business days to the time-to-therapy.

How Long Until You Receive Zetia in Hawaii?

From the moment a telehealth visit concludes, most Hawaii patients can have ezetimibe in hand within 24 to 72 hours via retail pharmacy, or within 5 to 7 days via mail-order.

The timeline breaks down as follows. A same-day telehealth visit that ends with an e-prescription transmitted before 3 p.m. Hawaii Standard Time allows same-day dispensing at retail pharmacies on Oahu and Maui that carry generic stock. The ACC/AHA recommends reassessing the lipid response 4 to 12 weeks after starting a new lipid-lowering agent [2], so the sooner the prescription is filled, the sooner you collect that first follow-up lipid panel and confirm efficacy.

If prior authorization is required, expect an additional 3 to 10 business days depending on the insurer's review queue. HMSA mandates a 72-hour response window for non-urgent PA requests under Hawaii's insurance code (HRS §431M-5), and most decisions arrive within that window when documentation is complete [13].

Mail-order 90-day fills ship from mainland fulfillment centers and arrive at Hawaii residential addresses in 3 to 7 days. Express mail options can reduce that to 2 to 3 days at additional shipping cost. Patients on outer islands should build in an extra 1 to 2 days.

Transferring a Zetia Prescription to Hawaii

A valid ezetimibe prescription issued in any U.S. state can be transferred to a Hawaii pharmacy, and telehealth providers can issue a new Hawaii prescription to replace an out-of-state script.

Federal law (21 CFR 1306) and Hawaii pharmacy statutes (HRS §461-15) allow the one-time transfer of a non-controlled prescription between licensed pharmacies. Because ezetimibe is not a controlled substance, there is no DEA scheduling barrier and no limit on the number of transfers between pharmacies in the same state. A pharmacist at a Longs Drugs or Walgreens in Hawaii can contact your mainland pharmacy by phone or electronic record system to execute the transfer.

If you are relocating to Hawaii permanently, the cleaner approach is to schedule a new telehealth visit with a Hawaii-licensed provider who can issue a fresh Hawaii prescription. This ensures the prescribing record is tied to a Hawaii-licensed clinician, satisfies any insurer's Hawaii-specific formulary requirements, and allows the provider to order a local lipid panel for ongoing monitoring. Most telehealth platforms can complete this visit and transmit the prescription within the same business day.

Ezetimibe Dosing, Efficacy, and Safety Data Relevant to Hawaii Patients

Ezetimibe 10 mg once daily is the only approved dose. It lowers LDL-C by 18 to 25% as monotherapy, and by a further 21 to 27% when added to any statin at any dose [1].

The IMPROVE-IT trial enrolled 18,144 patients stabilized after an ACS event and followed them for a median of 6 years. The simvastatin-ezetimibe arm achieved LDL-C of 53.7 mg/dL versus 69.5 mg/dL on simvastatin alone, and the composite MACE endpoint (cardiovascular death, major coronary event, or non-fatal stroke) occurred in 32.7% of the combination group versus 34.7% of the statin-monotherapy group (HR 0.936; 95% CI 0.89 to 0.99; P<0.001) [4]. The number needed to treat to prevent one MACE event over 7 years was approximately 50 patients [4].

A 2022 Cochrane systematic review of ezetimibe for the prevention of cardiovascular disease examined 26 randomized controlled trials (N=23,499) and concluded that ezetimibe reduces non-fatal MI by roughly 19% relative to control, with no signal of increased all-cause mortality (RR 0.98; 95% CI 0.91 to 1.05) [14]. Safety data from the same review found no statistically significant increase in myopathy, liver enzyme elevation, or cancer compared to placebo.

The FDA prescribing information notes that ezetimibe is not recommended during pregnancy (Category C) and should be used with caution in patients with moderate to severe hepatic impairment [5]. For Hawaii patients of Native Hawaiian, Filipino, or Japanese ancestry, there is no established pharmacogenomic variant that alters ezetimibe metabolism materially; CYP2C8 and SLCO1B1 variants that affect statin metabolism do not affect ezetimibe's glucuronidation pathway [15].

Drug interactions are limited. Cyclosporine raises ezetimibe AUC by 3.4-fold, and bile acid sequestrants (cholestyramine, colesevelam) reduce ezetimibe absorption by roughly 55% if administered simultaneously; the two drugs should be separated by 2 hours or more [5]. Fibrates may increase ezetimibe glucuronide levels and are generally co-prescribed with caution.

For patients with homozygous familial hypercholesterolemia (HoFH), ezetimibe 10 mg is approved as adjunct therapy and typically lowers LDL-C by an additional 15 to 20% when added to a statin plus lomitapide or evinacumab regimen. Hawaii's Queen's Medical Center and Kapiolani Medical Center have lipid clinics that manage HoFH patients.

What to Expect at Follow-Up After Starting Ezetimibe in Hawaii

A repeat fasting lipid panel 6 to 12 weeks after initiating ezetimibe confirms the LDL-C response. Most patients see a measurable reduction within 2 weeks, but the ACC/AHA 4-to-12-week recheck window allows time for a stable steady-state level to be measured [2].

If LDL-C has not fallen by at least 15% from baseline at the 12-week mark, the provider should verify medication adherence, check for drug interactions, and consider escalating to a PCSK9 inhibitor. The 2018 ACC/AHA guideline sets a threshold of LDL-C remaining above 70 mg/dL in very-high-risk patients despite maximally tolerated statin plus ezetimibe as the criterion for adding a PCSK9 inhibitor [2].

Routine liver function testing is not required during ezetimibe monotherapy after the baseline assessment. Patients who develop new-onset muscle pain or weakness should contact their provider for a CK level, particularly if they are also taking a statin, a fibrate, or niacin at the time.

Refills in Hawaii can be managed through the same telehealth platform used for the initial visit. Most providers set the initial prescription for 30 days with two refills, then transition to a 90-day supply once the lipid response is confirmed and the insurer's PA is approved. Annual lipid panels are the standard monitoring interval for stable patients on ezetimibe with LDL-C at goal, per ACC/AHA guidance [2].